In this solo episode, Omar Khateeb explores why QSBS could become an overlooked capital formation tool in MedTech.

QSBS was created to encourage investment in small American businesses, and Omar explains why it may fit MedTech investing well.

Medical device companies often require years of engineering, clinical development, FDA review, reimbursement, manufacturing, and commercialization before investors see liquidity. Those timelines can put MedTech at a disadvantage against fast sectors. QSBS offers another way to think about that patience.

Omar explains how qualifying investors may exclude portions of eligible federal capital gains after longer holding periods, while the 2025 changes raised the gross-assets threshold and exclusion limits.

He covers domestic C corporations, newly issued shares, secondary transactions, asset thresholds, and investor communication. He also examines how QSBS benefits may potentially pass through certain fund structures to eligible LPs, making after-tax performance relevant to fund strategy.

Omar also discusses Section 1045, which may allow qualifying investors in certain early exits to move proceeds into another eligible investment, potentially recycling MedTech capital back into innovation.

The core idea: MedTech asks investors to be patient, and QSBS may reward some of that patience.

DISCLAIMER
This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified professionals before making decisions.

Episode Breakdown:
00:00 Why QSBS Could Bring More Capital Into MedTech
01:05 Intro + The MedTech Funding Opportunity
01:25 Why MedTech Has a Capital Problem
03:05 How QSBS Could Change MedTech Investing
05:08 What Is Qualified Small Business Stock?
06:42 How QSBS Can Improve Investor Returns
08:17 Why Founders Should Understand QSBS
09:06 The 2025 QSBS Changes That Matter
10:43 Why MedTech Timelines Could Become an Advantage
12:39 Does MedTech Actually Qualify for QSBS?
14:26 Medical Devices vs Healthcare Services
16:12 What MedTech Founders Need to Know About QSBS
17:45 Primary Shares vs Secondary Shares
19:03 The $75M Gross Assets Threshold Explained
20:20 How Founders Should Discuss QSBS With Investors
22:07 Why MedTech Venture Funds Should Care About QSBS
23:40 How QSBS Could Improve After-Tax Fund Returns
25:12 Could QSBS Make MedTech More Competitive for Capital?
25:48 What Happens If a MedTech Company Sells Early?
26:47 How Section 1045 Could Recycle Capital Into MedTech
27:20 Why QSBS Could Become a MedTech Capital Formation Tool
28:03 What Founders and Venture Funds Should Do Now
29:02 The Bigger Opportunity for MedTech Investing
30:11 End

Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.

SUBSCRIBE
YouTube: https://www.youtube.com/@thestateofmedtech
LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/

FOLLOW THE STATE OF MEDTECH
LinkedIn: https://www.linkedin.com/company/thestateofmedtech/
Instagram: https://www.instagram.com/stateofmedtech/
TikTok: https://www.tiktok.com/@stateofmedtechpod
X: https://x.com/stateofmedtech
Facebook: https://www.facebook.com/stateofmedtech

FOLLOW OMAR M. KHATEEB
LinkedIn: https://www.linkedin.com/in/okhateeb/
Instagram: https://www.instagram.com/omar.m.khateeb/
TikTok: https://www.tiktok.com/@omar.m.khateeb
X: https://x.com/OmarMKhateeb
Facebook: https://www.facebook.com/OmarMKhateeb

Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf
Medtech CEO Camp in Boston: https://www.campcuriae.com/

#medtech #medtechindustry #venturecapital #startupfunding #founder

In this episode, Omar Khateeb speaks with Aneta Sottil, Partner at Andera Partners, about what makes a MedTech company investable as the investment bar continues to rise.

Aneta explains why early data is often no longer enough. Investors increasingly want stronger clinical validation, a clear path to market, reimbursement strategy, and proof that a technology can meaningfully improve patient care. She also explains the must-have vs nice-to-have test, why hardware matters, and why founder-investor alignment can shape commercialization and long-term value.

The conversation covers MedTech M&A, strategic buyers, surgical robotics, BCI, neuromodulation, wearable cardiac technologies, BPH innovation, and the role of AI, data analytics, and predictive capabilities.

DISCLAIMER
This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified professionals before making decisions.

Episode Breakdown:

00:00 AI and MedTech Investing
01:09 Meet Aneta Sottil
02:36 Andera’s MedTech Strategy
04:14 How Early Will Investors Go?
04:44 Early Stage Investing Has Changed
05:39 What MedTech Must Prove Today
06:47 Looking Beyond AI
08:12 Consolidation and MedTech
08:49 Fewer Strategic Buyers
10:48 Why Hardware Can Be Defensible
11:06 Why MedTech Must Integrate AI
12:01 Market Engineering and Growth
14:10 What Makes a Category Investable?
15:28 Must Have vs Nice to Have
17:28 MMI’s Microsurgery Robot
18:38 Value in Microsurgical Robotics
19:37 Are New Strategic Buyers Emerging?
20:45 Smaller Strategics and M&A
22:34 Is MedTech M&A Heating Up?
23:46 Boston Scientific and M&A
25:37 Neurotech and BCI
27:37 Why Neuromodulation Is Rising
28:49 Why Andera Invested in Spiro
30:10 De-Risking Early Stage MedTech
31:47 Neuromodulation for Asthma
33:12 Could Neuromodulation Transform Sleep?
34:48 Clinical Value vs Consumer Health
35:13 How Important Is Reimbursement?
37:34 Founder-Investor Alignment
38:13 How Founders Should Evaluate Investors
39:27 Painful Lessons From Investing
41:07 Commercialization Can Divide Teams
43:18 Supporting First-Time Founders
44:40 Experience vs Founder Conviction
45:54 Most Impactful MedTech Investments
47:09 Kestra and Wearable Defibrillators
49:39 Turning a Commercial Stall Into Growth
51:32 Why Patient Impact Matters
53:03 MedTech Innovations Investors Value
53:38 Exciting New Portfolio Companies
54:33 RiverMark and the BPH Opportunity
56:34 A Removable BPH Stent
58:36 Simple MedTech, Massive Value
59:03 Safety, Quality of Life and BPH
01:00:04 How Great Investors Keep Learning
01:00:51 Lessons From 25 Years of Investing
01:02:34 Staying Current on MedTech
01:03:02 Best MedTech Conferences
01:04:54 End

Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.

SUBSCRIBE
YouTube: https://www.youtube.com/@thestateofmedtech
LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/

FOLLOW THE STATE OF MEDTECH
LinkedIn: https://www.linkedin.com/company/thestateofmedtech/
Instagram: https://www.instagram.com/stateofmedtech/
TikTok: https://www.tiktok.com/@stateofmedtechpod
X: https://x.com/stateofmedtech
Facebook: https://www.facebook.com/stateofmedtech

FOLLOW OMAR M. KHATEEB
LinkedIn: https://www.linkedin.com/in/okhateeb/
Instagram: https://www.instagram.com/omar.m.khateeb/
TikTok: https://www.tiktok.com/@omar.m.khateeb
X: https://x.com/OmarMKhateeb
Facebook: https://www.facebook.com/OmarMKhateeb

Market Engineering Training:
https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf

Medtech CEO Camp:
https://www.campcuriae.com/

#medtech #medtechinnovation #venturecapital #medicaldevices #healthcareinnovation

Explore Showpad's VIP event, Excellence in the Field, in New York on October 8, 2026, for revenue leaders seeking practical AI and sales insights. Learn more.

In this episode, Omar Khateeb speaks with Gavin Leonard, CEO of MedTech Syndicates, and Steven Kaplan, Director of the American Urological Association Innovation Nexus, to explore how clinical insight, capital and commercialization can move MedTech ideas toward patient impact.

Steven shares how Nexus connects founders, clinicians, investors and strategics. Roughly 60 companies that presented over three years have collectively raised approximately $570 million. Gavin explains how clinicians can spot unmet needs and build investor confidence, sharing an example of a $4.2 million raise in 90 days.

They also discuss why FDA approval is only the beginning. Reimbursement, coding, physician adoption and strategic fit shape commercial success. From bladder cancer and fertility to incontinence, remote diagnostics and AI, the conversation explores urology's opportunities and how medical societies can support innovation year-round. For founders, clinicians and investors, it offers lessons on bringing ideas to patients.

DISCLAIMER
This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions.

Episode Breakdown:
00:00 Urology's Innovation Gap
01:23 The Future of Urology
03:35 Meet Dr. Steven Kaplan
04:50 Meet Gavin Leonard
05:53 Clinicians as Investors
07:02 New Funding Models
08:40 Creating AUA Innovation Nexus
10:18 Nexus Companies' $570M Raised
12:04 Market Engineering for MedTech
14:12 Why Urology?
16:32 Early-Stage Clinician Investors
20:15 When to Join Nexus
21:01 From Seed to Commercialization
25:14 How Nexus Works
26:46 Value Before Equity
27:45 Beyond FDA Approval
28:27 Building the Ecosystem
31:28 Rethinking MedTech Funding
33:28 Early-Stage Strategic Risk
35:56 Physicians Who Drive Adoption
37:44 Global Clinical Perspectives
39:48 Beyond Academic Centers
41:10 How Urologists Can Join
42:26 Inside a Nexus Event
44:51 Why Clinicians Attend
46:32 Year-Round Innovation
47:48 Validating Urology Startups
49:27 Rethinking Medical Meetings
51:46 Evolving Medical Societies
53:28 AUA's Innovation Approach
55:22 Urology's Biggest Opportunities
56:05 Bladder Cancer, Fertility and Incontinence
58:02 Remote Diagnostics
01:00:07 AI and Healthcare Efficiency
01:01:16 Final Thoughts and Resources
01:01:34 Outro
01:02:00 End

Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.

SUBSCRIBE

YouTube: https://www.youtube.com/@thestateofmedtech

LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/

FOLLOW THE STATE OF MEDTECHLinkedIn: https://www.linkedin.com/company/thestateofmedtech/

Instagram: https://www.instagram.com/stateofmedtech/

TikTok: https://www.tiktok.com/@stateofmedtechpod

X: https://x.com/stateofmedtech

Facebook: https://www.facebook.com/stateofmedtech

FOLLOW OMAR M. KHATEEB

LinkedIn: https://www.linkedin.com/in/okhateeb/

Instagram:https://www.instagram.com/omar.m.khateeb/

TikTok: https://www.tiktok.com/@omar.m.khateeb

X: https://x.com/OmarMKhateeb

Facebook: https://www.facebook.com/OmarMKhateeb

Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf

Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/

#medtech #urologyawareness #medicaldevices #healthcareinnovation #medtechindustry 

In this episode, Omar Khateeb speaks with Virginia Giddings, Vice President of Exploration at Edwards Lifesciences, about how major MedTech companies evaluate startups before commercial scale.

Virginia explains why Edwards builds early relationships in structural heart and heart failure, assessing patient need, clinical evidence, reimbursement, and strategic fit. She shares why founders need conviction, coachability, and candor, and how a relationship that began in 2015 grew into a heart failure monitoring business at Edwards.

They also discuss TAVR, AI, digital health, patient identification, and preparing for scale. The key takeaway: understand who needs your technology, how it reaches patients, and how it fits a potential partner’s strategy.

DISCLAIMER:

This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions.

Episode Breakdown:

00:00 What Founders Should Know About Strategics
01:02 Founder Coachability
02:04 MedTech Innovator Radar Forum
03:30 Meet Virginia Giddings
04:00 The VP of Exploration Role
05:10 How Edwards Finds Innovation
06:21 Why Edwards Engages Early
08:26 Early Strategic Relationships
09:48 Trust in Partnerships and M&A
11:07 Inside the Radar Forum
12:39 What Strategics Learn From Startups
14:23 Learning From Investor Feedback
15:53 Why Honest Feedback Matters
16:32 Market Engineering
18:29 The Value of Expert Feedback
19:15 The Personal Side of MedTech
20:53 How TAVR Saved Virginia’s Father
22:31 From Relationships to Acquisitions
23:51 Common Founder Mistakes
24:51 Start With Patient Need
26:34 Conviction and Humility
27:28 Why Investors Value Coachability
28:09 What Strategics Want in Founders
29:20 Candor During Due Diligence
30:07 Is Great Technology Enough?
31:16 Preparing Startups for Scale
33:02 Getting Strategics’ Attention
33:38 Researching Potential Acquirers
35:15 Technologies Edwards Is Seeking
37:12 The Structural Heart Focus
37:40 Final Thoughts
39:07 Connecting With Edwards
40:49 End

Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.

SUBSCRIBE

YouTube: https://www.youtube.com/@thestateofmedtech

LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/

FOLLOW THE STATE OF MEDTECHLinkedIn: https://www.linkedin.com/company/thestateofmedtech/

Instagram: https://www.instagram.com/stateofmedtech/

TikTok: https://www.tiktok.com/@stateofmedtechpod

X: https://x.com/stateofmedtech

Facebook: https://www.facebook.com/stateofmedtech

FOLLOW OMAR M. KHATEEB

LinkedIn: https://www.linkedin.com/in/okhateeb/

Instagram:https://www.instagram.com/omar.m.khateeb/

TikTok: https://www.tiktok.com/@omar.m.khateeb

X: https://x.com/OmarMKhateeb

Facebook: https://www.facebook.com/OmarMKhateeb

Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf

Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/

#medtech #medtechinnovation #medicaldevices #startupstrategy #healthcareinnovation

In this episode, Omar Khateeb speaks with David Hochman, Chairman & CEO of Orchestra BioMed, about a partnership-driven model for building, funding, and commercializing MedTech innovation.

Orchestra focuses on intellectual property, clinical development, and pivotal execution while partnering with global strategics that already have the infrastructure to manufacture, commercialize, and scale. Rather than building solely for acquisition, the company uses licensing and royalty structures to retain long-term participation in successful technologies.

David explains Orchestra’s partnership with Medtronic on AVIM therapy, designed to add blood-pressure-lowering capability to dual-chamber pacemakers. Orchestra could receive $500 to $1,600 for each AVIM-enabled pacemaker sold, while Medtronic would assume major commercialization responsibilities after key milestones.

They also discuss Virtue SAB, reimbursement, pricing, hospital economics, strategic fit, capital efficiency, clinical execution, AI, defensibility, and what strategics look for in emerging technologies.

For founders, the key lesson is simple: start with the end in mind.

DISCLAIMER

This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any security. Conduct your own due diligence and consult qualified professionals before making decisions.

EPISODE BREAKDOWN

00:00 What Makes a MedTech Company Attractive?
01:17 Meet Orchestra BioMed CEO David Hochman
02:38 From Venture Capital to Cardiovascular MedTech
04:10 Why the Traditional Innovation Model Is Changing
04:49 Orchestra BioMed’s New Business Model
08:29 Can Startups Become Big MedTech’s R&D Engine?
09:45 Build-to-Buy vs Partnership Model
13:55 Market Engineering and MedTech Growth
16:03 Inside Orchestra BioMed’s Partnerships
16:13 Medtronic and AVIM Therapy
18:20 Turning Pacemakers Into Therapeutic Platforms
21:02 The Renaissance of Cardiac Device Innovation
24:04 How Startups and Strategics Build Markets
24:39 Orchestra BioMed’s Medtronic Partnership
27:07 How the Royalty Model Works
27:41 Economics of AVIM-Enabled Pacemakers
31:16 Orchestra BioMed’s Second Pivotal Program
31:22 Virtue SAB and Drug-Coated Balloons
34:23 What Makes the Partnership Model Work?
36:23 What Makes Strategics Invest?
37:33 Why Reimbursement Matters
40:55 The Commercial Challenge Facing BCI Companies
41:49 Great Technology Needs a Path to Payment
43:39 Can Reimbursement Become More Transparent?
44:54 Why Innovators Return to MedTech
45:13 AI, Robotics and the Future of Medicine
46:55 Why MedTech Can Build Stronger Moats Than AI
49:04 How Orchestra Finds New Technologies
50:05 Could Orchestra Become a MedTech Acquirer?
52:17 Final Thoughts
52:37 Outro
53:10 End

Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.

SUBSCRIBEYouTube: https://www.youtube.com/@thestateofmedtechLinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/

FOLLOW THE STATE OF MEDTECHLinkedIn: https://www.linkedin.com/company/thestateofmedtech/

Instagram: https://www.instagram.com/stateofmedtech/

TikTok: https://www.tiktok.com/@stateofmedtechpod

X: https://x.com/stateofmedtech

Facebook: https://www.facebook.com/stateofmedtech

FOLLOW OMAR M. KHATEEB

LinkedIn: https://www.linkedin.com/in/okhateeb/

Instagram:https://www.instagram.com/omar.m.khateeb/

TikTok: https://www.tiktok.com/@omar.m.khateeb

X: https://x.com/OmarMKhateeb

Facebook: https://www.facebook.com/OmarMKhateeb

Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf

Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/

#medtech #medicaldevices #medtechinnovation #healthcareinnovation  #cardiovascularhealth 

In this episode of This Month in MedTech, Omar Khateeb speaks with Henry Peck, CBO at LSI | Intelligence, about the technologies, deals, and shifts shaping MedTech.

They examine Vitestro’s FDA authorization for autonomous blood draws, bringing physical AI into a high-volume workflow within the roughly $220 billion clinical laboratory services market. The technology could expand capacity, improve access to testing, and allow professionals to oversee multiple automated systems.

Omar and Henry also break down 13 deals totaling about $4 billion, consolidation among smaller public companies, and Boston Scientific’s $14.5 billion Penumbra acquisition. Is public MedTech separating into global platforms, early-stage innovators, and a shrinking middle?

The conversation covers autonomous stroke robotics, closed-loop spinal cord stimulation, and devices that respond to patient physiology. Abbott’s Google partnership raises another question: Will the biggest moat in metabolic health come from the CGM sensor or the intelligence built around continuous patient data?

The episode closes with a preview of LSI Europe 2026 and the forces shaping MedTech: AI, autonomy, data moats, strategic M&A, and intelligent devices.

DISCLAIMER

This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified professionals.

EPISODE BREAKDOWN

00:00 How AI Could Transform Healthcare Jobs
01:18 This Month in MedTech: August 2026
02:52 Why Public MedTech Is Consolidating
05:58 Is the Middle of the MedTech Market Disappearing?
07:06 The Return of Transformational MedTech M&A
11:11 Should MedTech Strategics Acquire Companies Earlier?
12:02 Market Engineering and MedTech Growth
14:09 How AI Could Create the Next MedTech Giants
17:59 The Rise of Autonomous Medical Robots
18:35 Vascular Robotics and Autonomous Blood Draws
24:04 Why Physical AI Goes Beyond Humanoid Robots
25:54 How AI Can Multiply Healthcare Workers
27:04 Will AI Replace Healthcare Jobs?
29:05 Autonomous Robotics for Stroke Treatment
30:54 The Race to Build Stroke Robotics
32:41 The Next Generation of Spinal Cord Stimulation
34:04 Saluda Medical and the Closed-Loop Opportunity
36:04 From Medical Devices to Intelligent Systems
37:03 Abbott and Google Enter the AI Health Race
37:26 The $15.5B Continuous Glucose Monitoring Market
40:05 Could CGM Data Become the New Healthcare Moat?
42:31 Google, OpenAI, and Apple Battle for the Health Intelligence Layer
44:16 Why Personal Health Context Creates Switching Costs
46:06 What to Expect at LSI Europe 2026
49:21 How MedTech Founders Can Prepare for LSI Europe
50:37 The Shift From Medical Devices to Physical AI
51:55 August 2026 MedTech Takeaways
52:38 Outro
53:20 End

Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.

SUBSCRIBE
YouTube: https://www.youtube.com/@thestateofmedtech
LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/

FOLLOW THE STATE OF MEDTECH
LinkedIn: https://www.linkedin.com/company/thestateofmedtech/
Instagram: https://www.instagram.com/stateofmedtech/
TikTok: https://www.tiktok.com/@stateofmedtechpod
X: https://x.com/stateofmedtech
Facebook: https://www.facebook.com/stateofmedtech

FOLLOW OMAR M. KHATEEB
LinkedIn: https://www.linkedin.com/in/okhateeb/
Instagram: https://www.instagram.com/omar.m.khateeb/
TikTok: https://www.tiktok.com/@omar.m.khateeb
X: https://x.com/OmarMKhateeb
Facebook: https://www.facebook.com/OmarMKhateeb

Market Engineering Training:
https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf

Medtech CEO Camp in Boston:
https://www.campcuriae.com/

#medtech #healthcareai #physicalai #medicalrobotics #medtechinnovation

In this episode, Omar Khateeb speaks with Eric S. Heinz, Founder and Managing Partner of Heinz Ventures, about creating MedTech value through product development, financing, commercialization, and strategic acquisition.

Eric brings 25 years of experience at Medtronic and Intuitive Surgical. His operating and M&A background shapes how he evaluates pre-seed and seed-stage companies.

A major theme is the widening early-stage MedTech capital gap. As venture firms move toward growth-stage investing, many founders are left between angel and institutional funding when product strategy, IP, prototypes, regulatory planning, and commercial foundations still need to be built.

Eric explains why operator-led diligence matters in an industry shaped by regulation, complexity, clinical workflows, and strategic buyers. He also explains why he prefers regulated Class II and higher technologies, whose barriers can support differentiation, premium pricing, and stronger exit value.

Omar and Eric explore how strategic buyers evaluate opportunities and why founders should consider acquisition pathways early. With 90% of venture-backed MedTech companies exiting through M&A, buyer logic should guide investment decisions.

They also cover neurotechnology, robotics, diagnostics, imaging, hardware moats, and the capital needed to reach commercial scale.

DISCLAIMER

This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold an investment or security. Conduct your own due diligence and consult qualified professionals before making decisions.

EPISODE BREAKDOWN

00:00 Why MedTech Investors Need Operating Experience
01:08 Intro + Meet Eric Heinz
03:50 From Engineering to a 25-Year MedTech Career
05:43 How Working in the OR Launched His Career
07:11 Why Operator Experience Matters in MedTech Investing
08:48 Why Eric Founded Heinz Ventures
10:51 How to Bring More Capital Into Early-Stage MedTech
12:43 Market Engineering and MedTech Growth
14:51 What Investors Misunderstand About Venture Capital
17:51 Conviction vs. Consensus in Venture Investing
18:10 Why MedTech Investors Need to Decide Faster
20:37 Inside the Heinz Ventures Investment Thesis
22:16 What Makes an Early-Stage MedTech Company Investable
24:12 How Eric Finds and Evaluates MedTech Startups
26:13 Helping Startups Reach Series A and M&A
27:18 Why Neurotech Is an Exciting Investment Opportunity
29:20 The Future of Imaging and Robotic Surgery
30:47 Why MedTech Hardware Has a Stronger Moat Than AI Software
32:58 Why M&A Makes MedTech Attractive to Investors
34:59 Where MedTech Investors Find Emerging Companies
35:59 The Opportunity in Early-Stage MedTech Investing
36:34 How to Connect With Eric Heinz
37:23 Outro
38:05 End

Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit https://GrowMyMedtech.com to book a free analysis.

SUBSCRIBE
YouTube: https://www.youtube.com/@thestateofmedtech
LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/

FOLLOW THE STATE OF MEDTECH
LinkedIn: https://www.linkedin.com/company/thestateofmedtech/
Instagram: https://www.instagram.com/stateofmedtech/
TikTok: https://www.tiktok.com/@stateofmedtechpod
X: https://x.com/stateofmedtech
Facebook: https://www.facebook.com/stateofmedtech

FOLLOW OMAR M. KHATEEB
LinkedIn: https://www.linkedin.com/in/okhateeb/
Instagram: https://www.instagram.com/omar.m.khateeb/
TikTok: https://www.tiktok.com/@omar.m.khateeb
X: https://x.com/OmarMKhateeb
Facebook: https://www.facebook.com/OmarMKhateeb

Watch Omar's Market Engineering Training:
https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf

Join Omar at Medtech CEO Camp in Boston:
https://www.campcuriae.com/

#medtech #medtechindustry #venturecapital #neurotechnology #medicaldevices

In this solo episode, Omar Khateeb examines why healthcare could become one of the most important beneficiaries of the next phase of AI, even as investors increasingly view the sector as a defensive alternative to the AI infrastructure trade.

The central distinction is between building intelligence and deploying intelligence. Healthcare already produces enormous amounts of medical imaging, ECG data, procedural video, robotic data, longitudinal patient information, and continuous physiological signals, yet the industry has historically struggled to extract value from that information at scale. Omar explores how AI could change that equation across radiology, cardiology, surgery, monitoring, and medical robotics by moving intelligence deeper into the clinical workflow and eventually into the physical device itself.

A major theme is physical AI, where medical systems progress from sensing what is happening, to predicting what may happen next, and eventually helping influence clinical action. That progression could make surgical robots, imaging platforms, cardiovascular systems, and therapeutic devices significantly more valuable over time.

The episode also covers simulation, synthetic data, intelligent hardware, installed-base network effects, healthcare venture investment, physician adoption, clinical evidence, and why market engineering remains essential even as AI models become more capable.

For MedTech founders, executives, and investors, the bigger question is no longer whether a product uses AI, but what intelligence fundamentally changes about the product, the workflow, and the clinical outcome.

DISCLAIMER

This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions.

Episode Breakdown:

00:00 Why Healthcare Could Be AI’s Biggest Opportunity

01:05 Healthcare Investing and the AI Trade

03:12 Why Investors Are Rotating Into Healthcare

05:05 The AI Trade vs the AI Economy

07:05 Why Healthcare Is Built for AI

11:12 How AI Is Transforming Medical Devices

15:24 From Predicting Outcomes to Delivering Care

18:59 Travis Kalanick’s Vision for the Physical World

19:36 Understand, Predict, Control

22:02 Why AI Could Make MedTech Hardware More Valuable

24:13 Data, Network Effects and the New MedTech Moat

33:19 Why Great AI Technology Still Needs Adoption

34:03 Market Engineering for Healthcare AI

39:14 How Healthcare Could Win Either Way

41:20 What MedTech Founders Should Learn From AI

42:32 What Real Physical AI Looks Like

44:01 Why MedTech Could Become AI’s Ultimate Proving Ground

45:02 Outro

Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.

SUBSCRIBEYouTube: https://www.youtube.com/@thestateofmedtechLinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/

FOLLOW THE STATE OF MEDTECHLinkedIn: https://www.linkedin.com/company/thestateofmedtech/Instagram: https://www.instagram.com/stateofmedtech/TikTok: https://www.tiktok.com/@stateofmedtechpodX: https://x.com/stateofmedtechFacebook: https://www.facebook.com/stateofmedtech

FOLLOW OMAR M. KHATEEBLinkedIn: https://www.linkedin.com/in/okhateeb/Instagram: https://www.instagram.com/omar.m.khateeb/TikTok: https://www.tiktok.com/@omar.m.khateebX: https://x.com/OmarMKhateebFacebook: https://www.facebook.com/OmarMKhateeb

Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf

Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/

#healthcareai #medtech #physicalai #medicaldevices #healthcareinnovation

In this episode, David Niewolny, Sr. Director and Global Head of Business Development for Healthcare and Medical at NVIDIA, joins Omar Khateeb to discuss how simulation, AI, open-source development, and GPU-scale computing are changing the way medical robots are built and trained.Healthcare robotics has an experience problem. Anatomy varies between patients, devices bend and interact with tissue, sensors can produce imperfect information, and rare edge cases are difficult to recreate consistently.NVIDIA’s healthcare simulation infrastructure gives developers a virtual environment where these conditions can be varied, repeated, and studied before teams move into expensive hardware-heavy development. David explains why the next frontier is not simply making simulation more visually realistic, but making it physics realistic enough to model anatomy, contact, friction, device behavior, and imaging variability across challenging scenarios.

The conversation also explores NVIDIA’s open-source strategy and why shared infrastructure could compress innovation cycles across MedTech. Instead of rebuilding the same foundational tools company by company, teams can focus more attention on clinical problems, proprietary data, workflows, AI applications, and measurable patient or hospital value. Omar and David also unpack the larger move toward software-defined, AI-enabled medical devices, where hardware becomes the foundation for continuously evolving applications, automation, and intelligence.

The episode offers a compelling view of how GPU simulation and open infrastructure could accelerate medical robotics while creating an entirely new software layer across the MedTech industry.

DISCLAIMER

This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions.

Episode Breakdown:

00:00 How Nvidia Could Transform Surgical Robotics

01:12 Intro + Meet David Niewolny

02:03 The Biggest Shift Happening in Surgical Robotics

04:19 Why Robots Need More Real World Experience

10:22 Market Engineering and MedTech Innovation

12:30 Why Nvidia Chose Open Source for Healthcare

24:08 The Golden Era of MedTech Innovation

27:33 How Nvidia Cut Robotic Training From 5 Hours to 2 Minutes

30:20 Could AI Create a New Generation of MedTech Startups?

31:59 How AI Could Change MedTech Investing and M&A

34:10 What Will Create Competitive Advantage in MedTech?

38:34 Nvidia, Edge AI and the Future of Medical Robotics

41:02 The Next Frontier in Surgical Robotics

41:49 Why MedTech Is Entering a Golden Age

42:56 Final Thoughts

43:17 Outro

Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.

SUBSCRIBEYouTube: https://www.youtube.com/@thestateofmedtechLinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/

FOLLOW THE STATE OF MEDTECHLinkedIn: https://www.linkedin.com/company/thestateofmedtech/Instagram: https://www.instagram.com/stateofmedtech/TikTok: https://www.tiktok.com/@stateofmedtechpodX: https://x.com/stateofmedtechFacebook: https://www.facebook.com/stateofmedtech

FOLLOW OMAR M. KHATEEBLinkedIn: https://www.linkedin.com/in/okhateeb/Instagram: https://www.instagram.com/omar.m.khateeb/TikTok: https://www.tiktok.com/@omar.m.khateebX: https://x.com/OmarMKhateebFacebook: https://www.facebook.com/OmarMKhateeb

Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf

Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/

#nvidia #surgicalrobotics #medtech #healthcareai #medicalrobotics

In this solo episode, Omar Khateeb translates some of Uber founder Travis Kalanick’s strongest lessons on fundraising, scale, leadership, and resilience into practical ideas for MedTech founders.The discussion begins with a powerful operating principle: companies can only scale as quickly as their organizations can solve the problems created by growth.

FDA clearance, new indications, commercialization, international expansion, and larger sales teams may look like progress, but every milestone also introduces new operational complexity. Omar then examines Travis’s fundraising philosophy and why creating alternatives can matter more than becoming emotionally attached to valuation. For MedTech founders, a dense and deliberate financing process can create urgency, preserve leverage, and help capital fund a stronger strategic position beyond the next regulatory milestone.

The episode also explores commercialization efficiency, market belief, ecosystem moats, and why early clinical support should eventually translate into easier adoption, faster training, stronger reference accounts, clearer reimbursement, and lower effort required to generate additional revenue.

Omar closes by examining founder resilience through the realities of MedTech, where clinical setbacks, regulatory uncertainty, financing pressure, and long commercialization timelines require founders to tolerate the right forms of adversity while continuing to evolve as leaders.

Ultimately, great MedTech companies need to become much larger than their technology by building the organizational, financial, commercial, and psychological capacity required to scale.

DISCLAIMER

This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions.

Episode Breakdown:

00:00 Why MedTech Founders Should Study Uber

01:05 Travis Kalanick’s Lessons for MedTech

03:35 Your Company Can Only Grow as Fast as It Solves Problems

06:18 Why Growth Creates More Complexity

08:05 The Founder as Problem Solver in Chief

10:58 Finding the Line Between Order and Chaos

13:42 How to Avoid Bureaucracy Without Creating Chaos

15:34 Fundraising Lesson: Process Over Valuation

18:08 How Uber Created Fundraising Leverage

22:20 Why Alternatives Give Founders More Leverage

26:09 How Uber’s Network Effects Created an Efficiency Edge

29:05 The MedTech Version of Uber’s Growth Strategy

31:01 Why Market Belief Becomes a Competitive Advantage

32:35 Your Real Moat May Be the Ecosystem

33:44 The Founder’s Capacity to Handle Adversity

36:22 Build the Machine Around the Product

37:50 Outro

Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.

SUBSCRIBEYouTube: https://www.youtube.com/@thestateofmedtechLinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/

FOLLOW THE STATE OF MEDTECHLinkedIn: https://www.linkedin.com/company/thestateofmedtech/Instagram: https://www.instagram.com/stateofmedtech/TikTok: https://www.tiktok.com/@stateofmedtechpodX: https://x.com/stateofmedtechFacebook: https://www.facebook.com/stateofmedtech

FOLLOW OMAR M. KHATEEBLinkedIn: https://www.linkedin.com/in/okhateeb/Instagram: https://www.instagram.com/omar.m.khateeb/TikTok: https://www.tiktok.com/@omar.m.khateebX: https://x.com/OmarMKhateebFacebook: https://www.facebook.com/OmarMKhateeb

Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf

Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/

#medtech #startupstrategy #fundraising #entrepreneurship #travis